Prof. Wolfgang Schramm
Prof. Dr. Dr. h.c.
Biography
Professor Schramm is specialized in haemostasis, internal and transfusion medicine. He received his doctor of Medicine in 1970 at the Ludwig-Maximilian-University. Since 1981 Professor Wolfgang Schramm has been head of the department of haemostasis at the university hospital of Munich, one of the biggest haemophilia and thrombosis centres in Germany. Since 1995 until 2011 head of the Dept. of transfusion medicine and haemostasis. He is a lecturer at the University of Munich. He has over 35 years experience in the field of haemostasis and bleeding disorders with a particular focus on haemophilia treatment. As add on to his clinical research he initiated several, patient-outcomes studies, cost-effectiveness evaluation analyses and meetings to enhance optimal use of blood products and clotting factor concentrates at a national and international level.
Key Publications
-
Schramm W, Gringeri A,, R. Ljung R, Berger K, Crispin A, Bulllinger M, Giangrande PL., Mackensen von S, Mantovani LG, Nemes L, and Serban M for the ESCHQoL Study Group. Haemophilia in Europe: The ESCHQoL study. Haemophilia in press
-
Berger K, Klein HG, Seitz R, Schramm W, Spieser JM. The Wildbad Kreuth initiative: European current practices and recommendations for optimal use of blood components. Biologicals. 2011 May;39(3):189-93.
-
Royal S, Schramm W, Berntorp E, Giangrande P, Gringeri A, Ludlam C, Kroner B, Szucs T; for the European haemophilia economics study group. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia. 2002 Jan;8(1):44-50.
-
Schramm W, Royal S, Kroner B, Berntorp E, Giangrande P, Ludlam C, Gringeri A, Berger K, Szucs T; for the European haemophilia economic study group.Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia. 2002 Jan;8(1):33-43.
-
Schramm W, Spannagl M, Bauer KA, Rosenberg RD, Birkner B, Linnau Y, Schwarz HP. Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol. 1993 Jun;129(6):753-6.
-
Schramm W, Roggendorf M, Rommel F, Kammerer R, Pohlmann H, Rasshofer R, Gürtler L, Deinhardt F. Prevalence of antibodies to hepatitis C virus (HCV) in haemophiliacs. Blut. 1989 Oct;59(4):390-2.
Key Institutions
-
Ludwig-Maximilians University
Rudolf-Marx-Stiftung
Munich, Germany -
University Hospital of Munich
Dept. of Transfusion Medicine,
Cell Therapeutics and Haemosasis
Munich, Germany
Current Positions/Chairs
-
ChairRudolf-Marx-Stiftung and Bluterbetreuung e.V.
Bayerische Kinderhilfe Rumänien e.V.
Hämophilie Stiftung
Paul and Linde Ottmann Stiftung -
Committee Member
BfArM, Paul Ehrlich Institute (PEI/DHR)
Committee for cross sectional guidelines in haemotherapy (BÄK)
Research Interests
-
Qutcome research and quality of life
-
Psychosocial counseling
-
Health economics
-
Diagnostic and treatment of thrombotic disorders
-
Congenital and acquired bleeding disorders
Publications
Challenges associated with access to recently developed hemophilia treatments in routine care – healthcare professionals’ perspectives.
Authors
Berger K, O’Rourke RH, Matteo Nicola DD, Batorova A, Kavakli K, Mannuccio PM, Wolfgang Schramm W, Rhonda BL, Aledort L on behalf of the International Prophylaxis Study Group.
Citation
Hematologica. 2024 Mar 1; 110(3):673-682. DOI: 10.3324/haematol.2024.285647
Are all licensed hemostatic agents for hemophilia therapy accessible to patients? Letter to the Editor
Authors
Berger K, Batorova A, Bohn RL, di Minno M, Mannucci P, Kavakli K, Schramm W, Aledort L on behalf of the International Prophylaxis Study Group
Citation
Haemophilia. 2022; 28:e256–e258. DOI: 10.1111/hae.14660
Securing reimbursement for patient centered haemophilia care: major collaborative efforts are needed.
Authors
Berger K, Feldman BM, Wasserman J, Schramm W, Blanchette VS, Fischer K on behalf of the Outcome Measures Expert Working Group of the IPSG
Citation
Haematologica; March 2016 101: 266-268
Hemophilia Prophylaxis: How can we justify the costs?
Authors
Feldman BM, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Hoots K, Mantovani L, Willan A, and Schramm W.
Citation
Haemophilia 2012 Sept; 18 (5): 680-684.
A review of health economic studies in hemophilia prophylaxis: a collaboration of the economics expert working group of the International Prophylaxis Study Group (IPSG).
Authors
Carcao M, Fischer K, Steen-Carlsson K, Schramm W, Feldman B, and Berger K.
Citation
Haemophilia 2008, 14 (S2), 133 # 24 PO 17.
A review of health economic studies in hemophilia prophylaxis: a collaboration of the economics expert working group of the International Prophylaxis Study Group (IPSG)
Authors
Carcao M, Fischer K, Steen-Carlsson K, Schramm W, Feldman B, and Berger K.
Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of the International Prophylaxis Study Group.
Authors
Nicholson A, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Mantovani L, Hoots K,, Schramm W, van Hout BA, Willan AR, and Feldman BM.
Citation
Haemophilia 2008 Jan; 14 (1):127 -132.
The economics of haemophilia prophylaxis: governmental and insurer perspectives. Proceedings of the Second International Prophylaxis Study Group (IPSG) Symposium.
Authors
Feldman BM, Aledort L, Bullinger M, Delaney FM, Doria AS, Funk S, Giangrande P, Lundin B, Manco-Johnson M, Miners A, Scriba PC, Srivastava A, Schramm W and Blanchette VS.
Citation
Haemophilia 2007 Nov; 13 (6): 745-749.